|
|
|
FGF23 associated bone diseases |
Eryuan Liao( ) |
| Institute of Metabolism and Endocrinology, the Second Xiangya Hospital, Central South University, Changsha 410011, China |
|
|
|
|
Abstract Recently, fibroblast growth factor 23 (FGF23) has sparked widespread interest because of its potential role in regulating phosphate and vitamin D metabolism. In this review, we summarized the FGF superfamily, the mechanism of FGF23 on phosphate and vitamin D metabolism, and the FGF23 related bone disease.
|
| Keywords
fibroblast growth factor 23
FGF receptor
phosphate metabolism
Klotho
bone disease
|
|
Corresponding Author(s):
Liao Eryuan,Email:eyliao007@yahoo.com.cn
|
|
Issue Date: 05 March 2013
|
|
| 1 |
Beenken A, Mohammadi M. The structural biology of the FGF19 subfamily. Adv Exp Med Biol 2012; 728: 1–24
doi: 10.1007/978-1-4614-0887-1_1 pmid:22396159
|
| 2 |
Donate-Correa J, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. Cytokine Growth Factor Rev 2012; 23(1–2): 37–46
doi: 10.1016/j.cytogfr.2012.01.004 pmid:22360923
|
| 3 |
Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 2012; 22(1): 61–86
doi: 10.1615/CritRevEukarGeneExpr.v22.i1.50 pmid:22339660
|
| 4 |
Jones SA. Physiology of FGF15/19. Adv Exp Med Biol 2012; 728: 171–182
doi: 10.1007/978-1-4614-0887-1_11 pmid:22396169
|
| 5 |
Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012; 26(4): 312–324
doi: 10.1101/gad.184788.111 pmid:22302876
|
| 6 |
Silver J, Naveh-Many T. FGF23 and the parathyroid. Adv Exp Med Biol 2012; 728: 92–99
doi: 10.1007/978-1-4614-0887-1_6 pmid:22396164
|
| 7 |
Razzaque MS. FGF23, klotho and vitamin D interactions: What have we learned from in vivo mouse genetics studies? Adv Exp Med Biol 2012; 728: 84–91
doi: 10.1007/978-1-4614-0887-1_5 pmid:22396163
|
| 8 |
Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005; 146(12): 5358–5364
doi: 10.1210/en.2005-0777 pmid:16123154
|
| 9 |
Burnett SM, Gunawardene SC, Bringhurst FR, Jüppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21(8): 1187–1196
doi: 10.1359/jbmr.060507 pmid:16869716
|
| 10 |
Rodríguez M, López I, Mu?oz J, Aguilera-Tejero E, Almaden Y. FGF23 and mineral metabolism, implications in CKD-MBD. Nefrologia 2012; 32(3): 275–278
pmid:22592418
|
| 11 |
Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012; 92(1): 131–155
doi: 10.1152/physrev.00002.2011 pmid:22298654
|
| 12 |
Kienitz T, Ventz M, Kaminsky E, Quinkler M. Novel PHEX nonsense mutation in a patient with X-linked hypophosphatemic rickets and review of current therapeutic regimens. Exp Clin Endocrinol Diabetes 2011; 119(7): 431–435
doi: 10.1055/s-0031-1277162 pmid:21553362
|
| 13 |
Bernheim J, Benchetrit S. The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant 2011; 26(8): 2433–2438
doi: 10.1093/ndt/gfr208 pmid:21543658
|
| 14 |
Kuro-o M. Klotho and βKlotho. Adv Exp Med Biol 2012; 728: 25–40
doi: 10.1007/978-1-4614-0887-1_2 pmid:22396160
|
| 15 |
Segawa H, Yamanaka S, Ohno Y, Onitsuka A, Shiozawa K, Aranami F, Furutani J, Tomoe Y, Ito M, Kuwahata M, Imura A, Nabeshima Y, Miyamoto K. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 2007; 292(2): F769–F779
doi: 10.1152/ajprenal.00248.2006 pmid:16985213
|
| 16 |
Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005; 310(5747): 490–493
doi: 10.1126/science.1114245 pmid:16239475
|
| 17 |
Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro-O M, Huang CL. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA 2008; 105(28): 9805–9810
doi: 10.1073/pnas.0803223105 pmid:18606998
|
| 18 |
Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N, Tomiyama K, Iijima J, Nabeshima Y, Fujioka M, Asato R, Tanaka S, Kojima K, Ito J, Nozaki K, Hashimoto N, Ito T, Nishio T, Uchiyama T, Fujimori T, Nabeshima Y. alpha-Klotho as a regulator of calcium homeostasis. Science 2007; 316(5831): 1615–1618
doi: 10.1126/science.1135901 pmid:17569864
|
| 19 |
Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, Razzaque MS, Rosenblatt KP, Baum MG, Kuro-o M, Moe OW. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24(9): 3438–3450
doi: 10.1096/fj.10-154765 pmid:20466874
|
| 20 |
Tohyama O, Imura A, Iwano A, Freund JN, Henrissat B, Fujimori T, Nabeshima Y. Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 2004; 279(11): 9777–9784
doi: 10.1074/jbc.M312392200 pmid:14701853
|
| 21 |
Hayes G, Busch A, L?tscher M, Waldegger S, Lang F, Verrey F, Biber J, Murer H. Role of N-linked glycosylation in rat renal Na/Pi-cotransport. J Biol Chem 1994; 269(39): 24143–24149
pmid:7929070
|
| 22 |
Rakugi H, Matsukawa N, Ishikawa K, Yang J, Imai M, Ikushima M, Maekawa Y, Kida I, Miyazaki J, Ogihara T. Anti-oxidative effect of Klotho on endothelial cells through cAMP activation. Endocrine 2007; 31(1): 82–87
doi: 10.1007/s12020-007-0016-9 pmid:17709902
|
| 23 |
Papaconstantinou J. Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination. Mol Cell Endocrinol 2009; 299(1): 89–100
doi: 10.1016/j.mce.2008.11.025 pmid:19103250
|
| 24 |
Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei BL, van Tits LJ, Kolsters G, Offerman JJ, Bilo HJ, Stalenhoef AF. Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy. Nephron Clin Pract 2004; 98(1): c3–c7
doi: 10.1159/000079921 pmid:15361698
|
| 25 |
Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW; PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22(10): 2909–2916
doi: 10.1093/ndt/gfm286 pmid:17517792
|
| 26 |
Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24(9): 2792–2796
doi: 10.1093/ndt/gfp191 pmid:19395730
|
| 27 |
Gordon PL, Frassetto LA. Management of osteoporosis in CKD Stages 3 to 5. Am J Kidney Dis 2010; 55(5): 941–956
doi: 10.1053/j.ajkd.2010.02.338 pmid:20438987
|
| 28 |
Maekawa Y, Ishikawa K, Yasuda O, Oguro R, Hanasaki H, Kida I, Takemura Y, Ohishi M, Katsuya T, Rakugi H. Klotho suppresses TNF-alpha-induced expression of adhesion molecules in the endothelium and attenuates NF-kappaB activation. Endocrine 2009; 35(3): 341–346
doi: 10.1007/s12020-009-9181-3 pmid:19367378
|
| 29 |
Nagai R, Saito Y, Ohyama Y, Aizawa H, Suga T, Nakamura T, Kurabayashi M, Kuroo M. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci 2000; 57(5): 738–746
doi: 10.1007/s000180050038 pmid:10892340
|
| 30 |
Nakamura T, Saito Y, Ohyama Y, Masuda H, Sumino H, Kuro-o M, Nabeshima Y, Nagai R, Kurabayashi M. Production of nitric oxide, but not prostacyclin, is reduced in klotho mice. Jpn J Pharmacol 2002; 89(2): 149–156
doi: 10.1254/jjp.89.149 pmid:12120757
|
| 31 |
Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 2008; 118(2): 722–734
pmid:18172553
|
| 32 |
Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S, Shimada T. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 2009; 24(11): 1879–1888
doi: 10.1359/jbmr.090509 pmid:19419316
|
| 33 |
Zhang R, Lu Y, Ye L, Yuan B, Yu S, Qin C, Xie Y, Gao T, Drezner MK, Bonewald LF, Feng JQ. Unique roles of phosphorus in endochondral bone formation and osteocyte maturation. J Bone Miner Res 2011; 26(5): 1047–1056
doi: 10.1002/jbmr.294 pmid:21542006
|
| 34 |
Lu Y, Yuan B, Qin C, Cao Z, Xie Y, Dallas SL, McKee MD, Drezner MK, Bonewald LF, Feng JQ. The biological function of DMP-1 in osteocyte maturation is mediated by its 57-kDa C-terminal fragment. J Bone Miner Res 2011; 26(2): 331–340
doi: 10.1002/jbmr.226 pmid:20734454
|
| 35 |
Razzaque MS. Osteo-renal regulation of systemic phosphate metabolism. IUBMB Life 2011; 63(4): 240–247
doi: 10.1002/iub.437 pmid:21438115
|
| 36 |
Murer H, Biber J. Phosphate transport in the kidney. J Nephrol 2010; 23(Suppl 16): S145–S151
pmid:21170872
|
| 37 |
Segawa H, Aranami F, Kaneko I, Tomoe Y, Miyamoto K. The roles of Na/Pi-II transporters in phosphate metabolism. Bone 2009; 45(Suppl 1): S2–S7
doi: 10.1016/j.bone.2009.02.003 pmid:19232403
|
| 38 |
Biber J, Hernando N, Forster I, Murer H. Regulation of phosphate transport in proximal tubules. Pflugers Arch 2009; 458(1): 39–52
doi: 10.1007/s00424-008-0580-8 pmid:18758808
|
| 39 |
Miyamoto K, Ito M, Tatsumi S, Kuwahata M, Segawa H. New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am J Nephrol 2007; 27(5): 503–515
doi: 10.1159/000107069 pmid:17687185
|
| 40 |
Laroche M, Boyer JF. Phosphate diabetes, tubular phosphate reabsorption and phosphatonins. Joint Bone Spine 2005; 72(5): 376–381
doi: 10.1016/j.jbspin.2004.07.013 pmid:16214071
|
| 41 |
Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74(2): 148–157
doi: 10.1038/ki.2008.130 pmid:18449174
|
| 42 |
Prié D, Ure?a Torres P, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009; 75(9): 882–889
doi: 10.1038/ki.2008.643 pmid:19190675
|
| 43 |
Wolf M. Fibroblast growth factor 23 and the future of phosphorus management. Curr Opin Nephrol Hypertens 2009; 18(6): 463–468
doi: 10.1097/MNH.0b013e328331a8c8 pmid:19770756
|
| 44 |
Wahl P, Wolf M. FGF23 in chronic kidney disease. Adv Exp Med Biol 2012; 728: 107–125
doi: 10.1007/978-1-4614-0887-1_8 pmid:22396166
|
| 45 |
Silver J. Molecular mechanisms of secondary hyperparathyroidism. Nephrol Dial Transplant 2000; 15(Suppl 5): 2–7
doi: 10.1093/ndt/15.suppl_5.2 pmid:11073267
|
| 46 |
Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299(4): F882–F889
doi: 10.1152/ajprenal.00360.2010 pmid:20685823
|
| 47 |
Saji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, Hatamura I, Shigematsu T. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron, Physiol 2009; 111(4): 59–66
doi: 10.1159/000210389
|
| 48 |
Günther T, Chen ZF, Kim J, Priemel M, Rueger JM, Amling M, Moseley JM, Martin TJ, Anderson DJ, Karsenty G. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 2000; 406(6792): 199–203
doi: 10.1038/35018111 pmid:10910362
|
| 49 |
Mughal MZ. Rickets. Curr Osteoporos Rep 2011; 9(4): 291–299
doi: 10.1007/s11914-011-0081-0 pmid:21968816
|
| 50 |
Henry HL. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 2011; 25(4): 531–541
doi: 10.1016/j.beem.2011.05.003 pmid:21872796
|
| 51 |
Fukumoto S, Shimizu Y. Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab 2011; 29(5): 507–514
doi: 10.1007/s00774-011-0298-0 pmid:21822586
|
| 52 |
Dai B, David V, Martin A, Huang J, Li H, Jiao Y, Gu W, Quarles LD. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS ONE 2012; 7(9): e44161
doi: 10.1371/journal.pone.0044161 pmid:22970174
|
| 53 |
Bergwitz C, Jüppner H. FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol 2012; 728: 41–64
doi: 10.1007/978-1-4614-0887-1_3 pmid:22396161
|
| 54 |
Gattineni J, Baum M. Genetic disorders of phosphate regulation. Pediatr Nephrol 2012; 27(9):1477–1487
|
| 55 |
Kinoshita Y, Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T, Fukumoto S, Fujita T. Mutational analysis of patients with FGF23-related hypophosphatemic rickets. Eur J Endocrinol 2012; 167(2): 165–172
pmid:22577109
|
| 56 |
Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 2012; 318(9): 1040–1048
doi: 10.1016/j.yexcr.2012.02.027 pmid:22421513
|
| 57 |
Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 2012; 30(1): 1–9
doi: 10.1007/s00774-011-0340-2 pmid:22167381
|
| 58 |
Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer 2011; 18(3): R53–R77
doi: 10.1530/ERC-11-0006 pmid:21490240
|
| 59 |
Owen C, Chen F, Flenniken AM, Osborne LR, Ichikawa S, Adamson SL, Rossant J, Aubin JE. A novel Phex mutation in a new mouse model of hypophosphatemic rickets. J Cell Biochem 2012; 113(7): 2432–2441
doi: 10.1002/jcb.24115 pmid:22573557
|
| 60 |
Khaliq W, Cheripalli P, Tangella K. Tumor-induced osteomalacia (TIO): atypical presentation. South Med J 2011; 104(5): 348–350
doi: 10.1097/SMJ.0b013e31821427db pmid:21606715
|
| 61 |
van der Rest C, Cavalier E, Kaux JF, Krzesinski JM, Hustinx R, Reginster JY, Delanaye P. Tumor-induced osteomalacia: the tumor may stay hidden! Clin Biochem 2011; 44(14-15): 1264–1266
doi: 10.1016/j.clinbiochem.2011.07.013 pmid:21843522
|
| 62 |
Magen D, Berger L, Coady M J, Ilivitzki A, Militianu D, Tieder M, Selig S, Lapointe J Y, Zelikovic I, Skorecki K. A loss-of-function mutation in NaPi-IIa and renal Fanconi’s syndrome. N Engl J Med 2010; 362(12): 1102–1109
doi: 10.1056/NEJMoa0905647 pmid:20335586
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
